Sight Sciences to Report Second Quarter Financial Results on August 1, 2024
18 Julio 2024 - 3:05PM
Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the
“Company”), an eyecare technology company focused on developing and
commercializing innovative, interventional technologies that
elevate the standard of care, today announced it will report
financial results for the second quarter ended June 30, 2024, after
the market close on Thursday, August 1, 2024. The Company’s
management will discuss the results during a conference call
beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Investors interested in listening to the
conference call may do so by accessing a live and archived webcast
of the event at www.sightsciences.com, on the Investors page in the
News & Events section. The webcast will be available for replay
for at least 90 days after the event.
About Sight SciencesSight
Sciences is an eyecare technology company focused on developing and
commercializing innovative and interventional solutions intended to
transform care and improve patients’ lives. Using minimally
invasive or non-invasive approaches to target the underlying causes
of the world’s most prevalent eye diseases, Sight Sciences seeks to
create more effective treatment paradigms that enhance patient care
and supplant conventional outdated approaches. The Company’s OMNI®
Surgical System is an implant-free glaucoma surgery technology (i)
indicated in the United States to reduce intraocular pressure in
adult patients with primary open-angle glaucoma; and (ii) CE Marked
for the catheterization and transluminal viscodilation of Schlemm’s
canal and cutting of the trabecular meshwork to reduce intraocular
pressure in adult patients with open-angle glaucoma. Glaucoma is
the world’s leading cause of irreversible blindness. The SION®
Surgical Instrument is a bladeless, manually operated device used
in ophthalmic surgical procedures to excise trabecular meshwork.
The Company’s TearCare® System is 510(k) cleared in the United
States for the application of localized heat therapy in adult
patients with evaporative dry eye disease due to meibomian gland
dysfunction (“MGD”), enabling clearance of gland obstructions by
physicians to address the leading cause of dry eye disease. Visit
www.sightsciences.com for more information.
Sight Sciences and TearCare are trademarks of
Sight Sciences registered in the United States. OMNI and SION are
trademarks of Sight Sciences registered in the United States,
European Union and other territories.
© 2024 Sight Sciences. All rights reserved.
Media contact:pr@SightSciences.com
Investor contact:Philip TaylorGilmartin
Group415.937.5406Investor.Relations@Sightsciences.com
Sight Sciences (NASDAQ:SGHT)
Gráfica de Acción Histórica
De Jul 2024 a Ago 2024
Sight Sciences (NASDAQ:SGHT)
Gráfica de Acción Histórica
De Ago 2023 a Ago 2024